✦ LIBER ✦

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

✍ Scribed by Davies, A J

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy with131I-Rituximab in

✍ Kang, Geon Wook; Kang, Hye Jin; Shin, Dong-Yeop; Gu, Ha Ra; Choi, Hong Seok; Lim 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 132 KB

Efficacy and safety of 90Y ibritumomab t

✍ Thomas E Witzig 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

131I-Tositumomab (Bexxar®)vs.90Y-Ibritum

✍ Andrei Iagaru; Erik S. Mittra; Kristen Ganjoo; Susan J. Knox; Michael L. Goris 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 200 KB

Yttrium-90 ibritumomab tiuxetan radioimm

✍ Maza, Sofiane; Gellrich, Sylke; Assaf, Chalid; Beyer, Marc; Spilker, Laura; Oraw 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 454 KB

Phase I study of radioimmunotherapy with

✍ Takashi Watanabe; Shoji Terui; Kuniaki Itoh; Takashi Terauchi; Tadahiko Igarashi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Phase I/II90Y-Zevalin (yttrium-90 ibritu

✍ Gregory A. Wiseman; Christine A. White; Michael Stabin; William L. Dunn; William 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 166 KB